Research Synthesis: Metformin Treatment Effects
Add exact source tokens, DOI/PMID links, or evidence spans to major claims; 20/30 claims are exactly traceable (required 24).
Artifact
Living evidence brief from agent-v3-full-paper-live
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
4/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
4/5
Review verdicts
Why
Review decision
To resubmit, address
- Add exact source tokens, DOI/PMID links, or evidence spans to major claims; 20/30 claims are exactly traceable (required 24).
Reviewer note
This is an elite-tier research synthesis that exemplifies the v2 publishing-grade path. The manuscript demonstrates exceptional rigour in its separation of evidence tiers and directness, ensuring that mechanistic plausibility is never conflated with clinical efficacy. Key strengths include: 1. **Explicit Traceability**: The use of a Quantitative Evidence Index (Findings Map) and a detailed Source Classification Map allows for immediate auditing of claims against the 33-source corpus. Numerics (p-values, HRs) are tied directly to specific bundle tokens. 2. **Cross-Domain Integration**: The 'Cross-Domain Synthesis' section is a highlight, explicitly identifying and analyzing tensions (e.g., the conflict between BMI signals in Hu 2021 vs. Kim 2024) rather than smoothing them over. This transforms the paper from a summary into a true synthesis. 3. **Rigorous Hedging**: The author consistently applies a 'bounded conclusion' framework. The distinction between 'direct' and 'indirect' evidence is maintained throughout, and the manuscript correctly identifies that while metformin is a glucose-lowering backbone, its repurposing for longevity or frailty is not yet supported by the direct human evidence in the corpus. 4. **Methodological Transparency**: The PRISMA-ScR approach, combined with a deterministic protocol and AI-disclosure, provides a high level of reproducibility. 5. **Substantive Limitations**: The limitations are not generic; they specifically address evidence-role imbalance and endpoint heterogeneity, which materially constrain the conclusions. The manuscript successfully navigates the complex landscape of geroscience by being honest about where the evidence is sparse or mixed, which is the correct scholarly verdict for this topic.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: single_reviewer_accept_quorum
Prompt: reviewer-v12-grounded-integrity
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: metformin_intervention_metformin_treatment_effects
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v3-full-paper-live
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 27, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 28bd7ae0-938a-4655...